Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7060207 | 0.86 | APEX1 (0.52) | APEX1BLMALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL3178301 | 0.80 | APEX1 (0.70) | APEX1BLMSMN1; SMN2CYP2D6CYP2C19 | |
| SCHEMBL19119195 | 0.80 | APEX1 (0.70) | APEX1BLMSMN1; SMN2CYP2D6CYP2C19 | |
| SCHEMBL3178292 | 0.80 | APEX1 (0.70) | APEX1BLMSMN1; SMN2CYP2D6CYP2C19 | |
| SCHEMBL11324280 | 0.76 | HTT (0.50) | ALDH1A1SMN1; SMN2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL7058387 | 0.74 | APEX1 (0.45) | APEX1BLMCASP1CASP7ALDH1A1 | |
| Oxiracetam SCHEMBL2596758 | 0.69 | APEX1 (1.00) | APEX1BLMCYP2C19TP53L3MBTL1 | |
| Oxiracetam SCHEMBL15789330 | 0.69 | APEX1 (1.00) | APEX1BLMCYP2C19TP53L3MBTL1 | |
| SCHEMBL14426907 | 0.69 | APEX1 (0.68) | APEX1BLMSMN1; SMN2TP53L3MBTL1 | |
| Oxiracetam SCHEMBL526050 | 0.69 | APEX1 (1.00) | APEX1BLMCYP2C19TP53L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077709-A1 | Neuronal death inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | claimed |
| US-6417220-B2 | A MEDICINE FOR PREVENTIVE/TREATMENT OF DISEASE CAUSED BY MITOCHONDRIAL MEMBRANE DEPOLARIZATION BECAUSE OF ELEVATION OF INTRACELLULAR CALCIUM ION CONCENTRATION; BENZODIAZEPINE RECEPTOR ANTAGONIST, E.G.,NEFIRACETAM; ANTIISCHEMIC AGENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-07-09 | — | — | US | claimed |
| EP-1180366-A9 | NEURONAL DEATH INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-04-24 | — | — | EP | claimed |
| EP-1180366-A1 | NEURONAL DEATH INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-02-20 | — | — | EP | claimed |
| US-20010051641-A1 | MITOCHONDRIAL MEMBRANE STABILIZER | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2001-12-13 | — | — | US | claimed |
| EP-1022029-A1 | NOOTROPIC AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-26 | — | — | EP | claimed |
| EP-0953356-A1 | MITOCHONDRIAL MEMBRANE STABILIZER | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-11-03 | — | — | EP | claimed |
| US-20040077709-A1 | Neuronal death inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| US-6417220-B2 | A MEDICINE FOR PREVENTIVE/TREATMENT OF DISEASE CAUSED BY MITOCHONDRIAL MEMBRANE DEPOLARIZATION BECAUSE OF ELEVATION OF INTRACELLULAR CALCIUM ION CONCENTRATION; BENZODIAZEPINE RECEPTOR ANTAGONIST, E.G.,NEFIRACETAM; ANTIISCHEMIC AGENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| EP-1180366-A9 | NEURONAL DEATH INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-04-24 | — | — | EP | disclosed |
| EP-1180366-A1 | NEURONAL DEATH INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-02-20 | — | — | EP | disclosed |
| US-20010051641-A1 | MITOCHONDRIAL MEMBRANE STABILIZER | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2001-12-13 | — | — | US | disclosed |
| EP-1022029-A1 | NOOTROPIC AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-26 | — | — | EP | disclosed |
| EP-0953356-A1 | MITOCHONDRIAL MEMBRANE STABILIZER | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077709-A1 | Neuronal death inhibitors | CASP3, CASP1, AIFM1 | APEX1 2493/4885BLM 4850/4885CASP1 2/4885 |
| US-20010051641-A1 | MITOCHONDRIAL MEMBRANE STABILIZER | TFAM, MDH2, NLN | APEX1 3472/4885BLM 4443/4885CASP1 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.